Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAT Combined With Corticosteroids for High Risk Acute GVHD
NCT04167514Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Jan 2020
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in graft-versus-host disease (GVHD) comparing AAT with Placebo (2 arms). Primary endpoint: Overall Response Rate to Acute Graft-versus-Host Disease (GVHD) Treatment at 28 days. Started Jan 2020; status: completed.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04167514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04167514.